Immatics (IMTX) Competitors $6.85 -0.03 (-0.44%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMTX vs. VRNA, RYTM, MLTX, JANX, XENE, EWTX, MRUS, ACAD, MOR, and TWSTShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Merus ACADIA Pharmaceuticals MorphoSys Twist Bioscience Verona Pharma (NASDAQ:VRNA) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment. Does the MarketBeat Community prefer VRNA or IMTX? Verona Pharma received 293 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 75.00% of users gave Immatics an outperform vote. CompanyUnderperformOutperformVerona PharmaOutperform Votes32380.55% Underperform Votes7819.45%ImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Which has more volatility & risk, VRNA or IMTX? Verona Pharma has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Is VRNA or IMTX more profitable? Verona Pharma has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Verona PharmaN/A -79.54% -43.49% Immatics -47.94%-15.90%-9.38% Does the media refer more to VRNA or IMTX? In the previous week, Immatics had 1 more articles in the media than Verona Pharma. MarketBeat recorded 3 mentions for Immatics and 2 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.30 beat Immatics' score of 0.15 indicating that Verona Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of VRNA or IMTX? 85.9% of Verona Pharma shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.8% of Verona Pharma shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, VRNA or IMTX? Verona Pharma has higher earnings, but lower revenue than Immatics. Verona Pharma is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma$5.62M601.01-$54.37M-$1.92-21.89Immatics$115.50M7.08-$104.98M-$0.66-10.38 Do analysts rate VRNA or IMTX? Verona Pharma currently has a consensus price target of $43.83, indicating a potential upside of 4.32%. Immatics has a consensus price target of $16.67, indicating a potential upside of 143.31%. Given Immatics' stronger consensus rating and higher possible upside, analysts plainly believe Immatics is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryImmatics beats Verona Pharma on 10 of the 19 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$817.59M$2.94B$5.01B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-10.3845.94135.0717.15Price / Sales7.08411.851,120.63116.80Price / CashN/A182.1040.5837.88Price / Book2.383.894.754.78Net Income-$104.98M-$42.21M$118.50M$225.60M7 Day Performance-4.99%-2.14%-1.85%-1.21%1 Month Performance-9.99%4.21%11.28%3.09%1 Year Performance-28.94%18.39%29.92%16.48% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics1.4231 of 5 stars$6.85-0.4%$16.67+143.3%-25.3%$817.59M$115.50M-10.38260VRNAVerona Pharma0.7085 of 5 stars$42.64+2.9%$43.83+2.8%+153.4%$3.46B$460,000.00-22.2730Gap DownRYTMRhythm Pharmaceuticals4.1088 of 5 stars$54.69-1.0%$63.70+16.5%+25.1%$3.36B$77.43M-12.76140Analyst ForecastNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.6288 of 5 stars$52.33+1.9%$79.88+52.6%-9.3%$3.34BN/A-40.842JANXJanux Therapeutics3.6249 of 5 stars$62.07+1.6%$89.90+44.8%+496.3%$3.26B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.8037 of 5 stars$41.27+3.0%$56.90+37.9%-5.8%$3.15B$9.43M-14.20251Insider TradeEWTXEdgewise Therapeutics2.7304 of 5 stars$32.99+19.4%$42.33+28.3%+261.7%$3.12BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeMRUSMerus2.8134 of 5 stars$42.90+0.2%$85.64+99.6%+61.7%$2.94B$35.93M-10.8437ACADACADIA Pharmaceuticals3.8511 of 5 stars$17.22-0.2%$25.60+48.7%-41.9%$2.87B$726.44M22.13510MORMorphoSys0.1298 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageTWSTTwist Bioscience2.5594 of 5 stars$47.83+0.7%$51.90+8.5%+36.7%$2.84B$312.97M-13.19990 Related Companies and Tools Related Companies Verona Pharma Competitors Rhythm Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Janux Therapeutics Competitors Xenon Pharmaceuticals Competitors Edgewise Therapeutics Competitors Merus Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Twist Bioscience Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
